For research use only. Not for therapeutic Use.
Eflucimibe, also known as F-12511; L-0081, is an ACAT inhibitor potentially for the treatment of atherosclerosis and hyperlipidemia. F 12511 regulates endogenous hypercholesterolemia in a synergistic manner in New Zealand rabbits fed a casein-enriched diet. F 12511 inhibited ACAT activity with IC(50) values of 3, 7, and 71 nM, respectively. In vivo, orally administered F 12511 displayed high potency and efficacy as an antihypercholesterolemic compound in different cholesterol-fed animals (rat, guinea-pig, rabbit).
| Catalog Number | I006627 |
| CAS Number | 202340-45-2 |
| Synonyms | Eflucimibe; F-12511; L-0081; F12511; L0081.;(S)-2-(dodecylthio)-N-(4-hydroxy-2,3,5-trimethylphenyl)-2-phenylacetamide |
| Molecular Formula | C29H43NO2S |
| Purity | ≥95% |
| Target | ACAT inhibitor |
| Solubility | Soluble in DMSO |
| Storage | 0 - 4°C for short term or -20 °C for long term |
| IUPAC Name | (2S)-2-dodecylsulfanyl-N-(4-hydroxy-2,3,5-trimethylphenyl)-2-phenylacetamide |
| InChI | InChI=1S/C29H43NO2S/c1-5-6-7-8-9-10-11-12-13-17-20-33-28(25-18-15-14-16-19-25)29(32)30-26-21-22(2)27(31)24(4)23(26)3/h14-16,18-19,21,28,31H,5-13,17,20H2,1-4H3,(H,30,32)/t28-/m0/s1 |
| InChIKey | ZXEIEKDGPVTZLD-NDEPHWFRSA-N |
| SMILES | CCCCCCCCCCCCSC(C1=CC=CC=C1)C(=O)NC2=C(C(=C(C(=C2)C)O)C)C |
| Reference | </br>1:Inhibition of acyl-CoA cholesterol acyltransferase by F12511 (Eflucimibe): could it be a new antiatherosclerotic therapeutic? López-Farré AJ, Sacristán D, Zamorano-León JJ, San-Martín N, Macaya C.Cardiovasc Ther. 2008 Spring;26(1):65-74. doi: 10.1111/j.1527-3466.2007.00030.x. Review. PMID: 18466422 </br>2:Determination of solubility profiles of eflucimibe polymorphs: experimental and modeling. Teychene S, Autret JM, Biscans B.J Pharm Sci. 2006 Apr;95(4):871-82. PMID: 16489606 </br>3:A three step supercritical process to improve the dissolution rate of eflucimibe. Rodier E, Lochard H, Sauceau M, Letourneau JJ, Freiss B, Fages J.Eur J Pharm Sci. 2005 Oct;26(2):184-93. PMID: 16081259 </br>4:Spectrofluorimetric study of eflucimibe-gamma-cyclodextrin inclusion complex. Mesplet N, Morin P, Ribet JP.Eur J Pharm Biopharm. 2005 Apr;59(3):523-6. PMID: 15760733 </br>5:Development of a method for simultaneous determination of eflucimibe and its three major metabolites in rat plasma by liquid chromatography/electrospray tandem mass spectrometry: a preliminary study. Mesplet N, Morin P, Ribet JP.Rapid Commun Mass Spectrom. 2005;19(3):297-302. PMID: 15645487 </br>6:Evolution of the interaction of a new chemical entity, eflucimibe, with gamma-cyclodextrin during kneading process. Gil A, Chamayou A, Leverd E, Bougaret J, Baron M, Couarraze G.Eur J Pharm Sci. 2004 Oct;23(2):123-9. PMID: 15451000 </br>7:Eflucimibe. Pierre Fabre/Eli Lilly. Burnett JR.Curr Opin Investig Drugs. 2003 Mar;4(3):347-51. Review. PMID: 12735237 </br>8:[Crystalline polymorphism of eflucimibe]. Ribet JP, Pena R, Chauvet A, Patoiseau JF, Autin JM, Segonds R, Basquin M, Autret JM.Ann Pharm Fr. 2002 May;60(3):177-86. French. PMID: 12050596 |
